Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral melphalan pharmacokinetics and ASCT conditioning in newly diagnosed multiple myeloma
ChiCTR2500097863Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of melphalan in multiple myeloma (MM) (5 arms), sponsored by Ruijin Hospital. Primary endpoints: Safety and tolerability, Efficacy and 1 more. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
melphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2500097863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097863.